Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 67% of net sales are generated from international locations, exposing the company to foreign currency fluctuations.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Net Sales | $461.1 | $1,289.2 |
| Gross Profit | $260.5 | $731.4 |
| Gross Margin | 56.5% | 56.7% |
| Operating Income | $67.4 | $174.7 |
| Net Income (Attributable to Bio-Rad) | $38.5 | $106.8 |
| Diluted EPS | $1.38 | $3.85 |
| Cash and Cash Equivalents | $554.2 | $554.2 (Balance Sheet) |
| Short-term Investments | $87.9 | $87.9 (Balance Sheet) |
| Total Debt (Long-term + Current) | $744.0 | $744.0 (Balance Sheet) |
| Operating Cash Flow (9 Months) | N/A | $209.4 |
Material Changes vs. Prior Period
- Revenue: Net sales increased 4.4% in the third quarter compared to the prior year, driven by an 11.1% increase on a currency-neutral basis. For the nine-month period, reported sales declined 2.1%, but currency-neutral sales grew 5.9%.
- Segment Performance:
- Life Science: Sales declined 4.1% in Q3 and 6.9% for the nine months, primarily due to weakened demand in Europe and the U.S. and a slowdown in large capital equipment sales.
- Clinical Diagnostics: Sales increased 9.3% in Q3 and 0.8% for the nine months. Growth was driven by the BioPlex 2200 system, blood virus, and immunology products.
- Profitability: Gross margins improved to 56.5% in Q3 (from 54.4% in 2008) and 56.7% for the nine months (from 54.4% in 2008). Improvements were attributed to better manufacturing overhead absorption, offshore manufacturing shifts, and lower royalty payments due to patent expirations.
- Debt and Interest: Interest expense increased significantly ($6.3 million in Q3) following the issuance of $300 million in 8.0% Senior Subordinated Notes in May 2009. Total indebtedness rose to $744.0 million.
- Cash Flow: Net cash provided by operating activities for the nine months ended September 30, 2009, was $209.4 million, a substantial increase from $113.0 million in the prior year period, largely due to flat inventory levels compared to significant inventory build-up in 2008.
Guidance, Outlook, and Risks
- Outlook: Management expects cash flow from operations and available credit facilities ($229.0 million available) to be adequate for operations, R&D, capital additions, and future acquisitions. No specific numerical guidance for future quarters was provided in this text.
- Acquisitions: On October 23, 2009, Bio-Rad announced an agreement to acquire certain diagnostic businesses of Biotest AG for approximately $67 million, expected to close in Q1 2010. The company continues to evaluate other potential acquisitions.
- Risks and Contingencies:
- Economic Conditions: Global recession and credit market instability may delay customer capital spending and affect liquidity.
- Currency: Significant strengthening of the U.S. dollar could adversely affect international results when translated.
- Debt Covenants: The company is subject to leverage, interest coverage, and net worth covenants. While compliant as of September 30, 2009, future economic conditions could impact compliance.
- Legal: The company is involved in various legal proceedings but does not believe they will have a material adverse effect.
Investor Verification Checklist
- Debt Servicing: Verify the impact of the new $300 million 8.0% Notes on future interest coverage ratios and cash flow availability.
- Currency Sensitivity: Assess the exposure of the 67% international sales to U.S. dollar strength and the effectiveness of hedging strategies.
- Acquisition Integration: Monitor the closing and integration of the Biotest AG acquisition and the DiaMed Holding AG noncontrolling interest buyout.
- Capital Spending Trends: Track the recovery of large capital equipment sales in the Life Science segment, which remains weak.
- Inventory Management: Confirm that inventory levels remain stable to sustain the improved operating cash flow seen in the first nine months of 2009.